Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VANI from $7.80 on volume to $1.98 today.... fire sale with all this going for them https://ragingbiotechbuzz.blogspot.com/2024/02/clock-ticking-vivani-prepares-to.html
Omega Therapeutics: Biotech Stock with Big Upside - Read here
Omega Therapeutics (OMGA) presents a compelling investment opportunity due to its pioneering approach to medicine with programmable epigenomic-controller mRNA medicines. The company's unique Next-Gen mRNA Platform addresses the limitations of other mRNA therapies, promising fewer side effects and the ability to target previously undruggable diseases. A recent collaboration with Novo Nordisk, a pharma giant, to develop an obesity drug using Omega's platform speaks volumes about the company's technology potential and opens doors for future deals. Analysts at Wedbush and H.C. Wainwright share the optimism, with $12.00 price targets and buy ratings, but the potential is considered much bigger. Compared to established mRNA players, Omega trades at a significantly lower price, offering tremendous potential for future growth. The company has a diverse pipeline of promising candidates across various disease areas, and it is listed on the NASDAQ-GS, a market reserved for established and respected companies. Additionally, Omega is backed by Flagship Pioneering, the venture capital firm that propelled Moderna to success, signaling confidence in Omega's potential to disrupt the healthcare landscape. The company's digital and AI-based computational engine enables rapid design and development of therapeutic candidates, accelerating discovery and preclinical development. Omega's versatile platform could tackle not just fatty liver, but a variety of diseases. Despite a recent dip in share price, astute investors see this as a buying opportunity, with potential for a rapid climb past $10 and long-term prospects extending far beyond a $60 share price. Omega Therapeutics has the potential for significant growth, similar to other mRNA companies of the past. The company's innovative approach to developing a new class of programmable epigenomic mRNA medicines has garnered attention and excitement within the biotechnology industry. With the upcoming release of updated clinical data and the initiation of expansion cohorts, Omega Therapeutics is on the brink of potentially revolutionizing cancer treatment and solidifying its position as a leader in precision epigenomic control. The company's groundbreaking approach, promising data, and industry partnerships paint a strong picture, attracting substantial and ongoing investment. Omega's future looks bright, and it is considered one of the companies that is setting up for significant gains in 2024, fueled by multibillion-dollar deals, upbeat clinical results, and cutting-edge medical advances like CRISPR gene-editing hitting prime-time and programmable epigenomic-controllers being a safer option. Therefore, Omega Therapeutics (OMGA) represents an attractive investment opportunity with the potential for significant growth and a unique position in the burgeoning field of programmable epigenomic-controller mRNA medicines.
Omega Therapeutics is a leading company in the field of programmable epigenomic-controller mRNA medicine for several compelling reasons:
Remember, the patent landscape is constantly evolving, so staying updated on patent filings and granted inventions in this field remains crucial for tracking the potential leaders.
The Promising Future of Vitargus: A New Chapter in Retinal Tamponade?
The management of retinal detachments (RDs) has long relied on retinal tamponades, commonly gas bubbles or silicone oil. While effective, these options come with limitations and potential complications. Enter Vitargus, a novel injectable polymer under development, presenting a potential paradigm shift in retinal tamponade. Here's how Vitargus could become a game-changer:
Addressing the Drawbacks of Current Tamponades:
Long-term complications: Gas bubbles require repeated injections, posing risks like cataract formation and elevated intraocular pressure (IOP). Silicone oil often necessitates additional surgery for removal, carrying infection and vision-threatening risks. Vitargus, being biodegradable and potentially requiring fewer injections, could mitigate these long-term concerns.
Visual distortions: Gas bubbles and silicone oil can cause visual distortions due to their refractive properties. Vitargus, with its similar refractive index to vitreous humor, may offer improved visual clarity compared to traditional tamponades.
Discomfort and limitations: Gas bubbles can induce floaters and discomfort, while silicone oil limits certain activities like flying. Vitargus, by potentially causing minimal visual disturbances and allowing for a wider range of activities, could improve patient quality of life.
Unlocking Potential Advantages of Vitargus:
Targeted and sustained tamponade: Vitargus, designed to gel within the vitreous cavity, could provide targeted and sustained tamponade, potentially leading to improved anatomical reattachment and faster visual recovery.
Biodegradability and biocompatibility: Biodegradable Vitargus eliminates the need for removal surgery, simplifying the treatment process and minimizing potential complications. Its biocompatibility also reduces the risk of inflammatory reactions compared to silicone oil.
Adjustable tamponade pressure: Vitargus formulations may allow for tailoring the tamponade pressure based on individual needs and RD severity, potentially optimizing outcomes.
The Road Ahead:
While preliminary investigations show promising results, further clinical trials are crucial to definitively establish Vitargus's efficacy and safety compared to established tamponades. Nevertheless, its potential to address the limitations of current options and offer several unique advantages positions Vitargus as a noteworthy innovation in the field of retinal detachment management.
Why Vitargus® Could Push ABVC Shares Beyond $35: A Factual Analysis
While predicting the future of any stock is inherently uncertain, here are some factual reasons why Vitargus®, ABVC's breakthrough retinal surgery implant, has the potential to drive its share price above $35:
1. Market Size and Growth:
The global market for retinal surgery devices is expected to reach $4.3 billion by 2029, driven by an aging population and rising demand for minimally invasive procedures. (Source: iHealthcare Analyst, Inc.)
Vitargus® targets a specific segment of this market with its unique biodegradable implant design, potentially capturing a significant share.
2. Game-Changing Technology and Potential Advantages:
Vitargus® eliminates the need for a second surgery to remove the implant, unlike traditional methods, potentially leading to faster recovery times and improved patient comfort.
Early studies suggest it could also eliminate the need for post-operative face-down positioning, further improving patient experience.
These advantages, if proven in Phase II trials, could make Vitargus® a highly sought-after product and differentiate it from existing options.
3. Positive Analyst Sentiment and Upcoming Data:
Several analysts have expressed optimism about Vitargus® and its potential impact on ABVC's future.
The upcoming Phase II trial data release in Q4 2023 is a critical catalyst that could significantly impact the stock price. Positive results could trigger a surge in investor confidence and lead to upward revaluations.
4. Potential Partnerships and Distribution Agreements:
Major pharmaceutical companies are reportedly interested in partnering with ABVC for Vitargus® distribution and/or manufacturing, potentially injecting significant revenue into the company.
Early distribution agreements in Asia and Australia could further boost ABVC's financials and attract further investor interest.
5. Valuation Potential:
Some analysts believe that ABVC's current valuation does not fully reflect the potential of Vitargus® and its future revenue streams.
A successful commercialization of Vitargus® could significantly increase ABVC's earnings and justify a higher share price, potentially exceeding $35.
Important Caveats:
The success of Vitargus® is not guaranteed, and the market reaction to the Phase II data remains uncertain.
The overall market conditions and investor sentiment can also impact ABVC's share price.
This information is for educational purposes only and should not be considered financial advice.
Conclusion:
While pushing past $35 is not a guaranteed outcome, Vitargus® presents a compelling case for potential future growth of ABVC. Its innovative technology, market potential, and upcoming data release make it a story worth watching closely for investors interested in healthcare and disruptive medical devices.
Remember, always conduct your own research and consult with a qualified financial advisor before making any investment decisions.
1) Electronic Communication Networks ARCA & NSDQ do not communicate by design.This often creates a cross locked situation where the bid and ask are temporarily the same - in extended hours trading sessions it's easier to spot. What that means for example is that company XYZ can have a bid price of $5.01 routed through ARCA and a $5.01 ask price routed through NASDAQ creating an equal bid and ask that won't execute. If the bid on ARCA is increased to $5.02 a lightning fast computer takes the trade. The result is free money multiplied by every share on the bid being shaved .009 cents while making themselves (market makers) look good to the bidding retail customer. The bidder is told he received a price adjustment in his favor of .001 per share or a $5.019 fill. On the other side the ask never new a better bid existed. In effect the market maker took .009 from the bidder because a better ask existed. lf the trade was 10,000 shares in size and multiplied by .009, that's a $90 profit on one trade without risk to the market maker. How do I know about this? Once, I was on both sides of the trade and received the adjustment of .001 per share and nothing on the other side. Multiply this by every trade situation like this going on in every stock every day in the market and you get the picture.
2) On stocks over $1 in share price, notice the fractional trades executing on level II. Retail traders\investors can't place bids or asks in fractional trade format for stocks trading over $1.00. Something like the situation in number #1 above has taken place every time you see a fractional trade in these stocks. There are more Electronic Communication Networks than just ARCA and NASDAQ used in the example in #1.
3) You will notice ADF trades on level II as having been executed often - this is a relatively recent scam as if retail wasn't already at a disadvantage. ADF stands for alternative display facility in effect a "dark pool" that can't be seen by retail investors. Since retail can't see these bids or asks on level II this allows the market makes to circumvent the rules that govern the best bid and ask hierarchy for execution always placing them at the front of the trading line when their lightning fast computers see a favorable trade.
4) Day traders often buy high at the ask to get the large quantity of shares required to overcome a commission on a small move. A buy at the ask is fast and will not tip the other traders off as to the number of shares taken till after the fact. If not done fast at the ask the price would move against the traders own effort before they have a large position. This means the trader at least temporarily holds shares higher than the current best bid creating an immediate loss and a bigger loss if the trade turns out to be a bust. A wide bid ask spread is often maintained by the market makers when they see high volume and volatility together. If a trader jumps in between the spread with the intent to close the spread a lightning fast machine can take that effort and make a profitable trade for the market makers.This is done instantly inside the ADF and other dark pools that exist between the spread and hidden from retail. This also serves to maintain the desired spread the market makers and not retail dictate.
5) Shorting: Brokers and market makers work in conjunction with one another controlling who can short and who pays a fee to borrow shares, if they allow retail to borrow shares at all. Even legitimate shorting serves to dilute the value of the shares that exist in retail hands. How you may ask? Example: 10 shares exist in stock XYZ and are in your account, then the broker you trust loans them out to someone. That someone (often a market maker) sells your own shares to the favorable bid and you lose the favorable bid pressure. Now the person sold to owns 10 shares and you hold 10 shares or believe you hold 10 shares.That in effect creates 20 shares out of 10. Extend the example to higher share counts and again you get the picture. That's not even going into the naked shorting where shares are printed before seeing if any exist to borrow. The markets trade just fine with no shorting at all and have at times. Shorting is the biggest fraud perpetrated on the investing public and a destroyer of any company trying to raise capital while shorts are attacking their reputation. Market makers should not be allowed to be in the business of deciding what companies should be taken down just because they may be a "bad investment". Real people are already invested taking away the argument about helping the public. What market makers are doing is helping themselves to profit through shorting an easy target. Companies are often weak because the rampant shorting destroyed their ability to raise capital in the first place. If a company is such a "bad risk" that retail must be protected from higher share prices why are these companies on the exchange in the first place? A higher share price does not hurt investors entry any more than a low share price. An investors wallet and not the share price dictates the share number held. A $2000 investment is still a $2000 investment regardless of share price you still lose $2000 if the stock goes to zero. Free markets and not market makers should ultimately decide what company survives or not. Don't expect to see that because it's not in their best interest where helping themselves to your money is.
6) Shorts have the advantage because they can show large sells (ask price) with no intention of having them executed to "spook" the price down.The short advantage is maintained since longs would like in at the lowest price possible. This greed prevents the longs from "hitting the ask" and punishing the shorts who attempt the manipulation. If the longs were hitting the ask constantly the shorts would become overextended. Longs are at risk when playing the same game (showing large bids) because sellers exist more readily and are scared into selling by the shorts who are probably using those sellers (longs) own shares against them.. Shorts, as explained have future longs as allies since future longs help deceive the current longs to gain a more favorable entry price.
Don't forget any type of shorting is diluting the share count\value and can double the sellers... when shorts sell they do it in an effort to drive down the stock price. When shorts buy to cover they can use extended hours, lunch hour or any time that will not spook the price higher and they can hide their buy sizes. Advantage shorts.
7) Market makers have cover stories explaining why a stock is going down and preventing their manipulation from being discovered as the real cause of price decline. Example blame an earnings report even if good. Sell the news is a saying and they will use it! If the news is bad, use that excuse for sure. Not bad enough news? Just say that investors didn't like something about it. If no news exists blame the overall market conditions or an election, war, event in the news that could effect stocks etc.... the list is endless. It couldn't be the large sell orders that shorts show to "spook" the bids right on the opening bell to choke off the buying volume right? Here's a kicker if a retail bidder (long) shows an order in attempt to move the price higher the market makers can choose not to display that bid because they will say it's and attempt at manipulation. As if the shorts are not engaged in manipulation... lol.
With the siphoning of money from retail market participants happening will long term investors get rewarded for being long term investors? Maybe, however, far less than should be the case since the money is now in the market makers hands vs retail where the money would continue to be invested. Make no mistake retail is being cheated every day, long and short term investors alike. Even stocks in 401K's lose value when the market makers short stocks. No matter the investment time horizon that equals bad news for retail investors. If you're one of the few investors who make good choices long term and comes out ahead, you're not as far ahead as you could have been without the corruption.
The solution? Take this information and demand that politicians clean up the markets. The best place to start is getting rid of all forms shorting. The market does work without shorting just fine! It just doesn't work as well for the market makers who will claim it's needed and other big players they support will agree with them. Who should the markets be designed to help retail investors and the companies trying to create and maintain a business or large players with unfair advantage who feed off those two groups?
ABVC BioPharma: A Comprehensive Guide To Discover The True Value Of Your Shares:
11/01/2023 7:45 P.M.
Key Highlights
• ABVC Biopharma has gained interest in the investment community due to strategic partnerships in neurological and mental health treatments.
• The company's CNS drugs targeting MDD and ADHD have definitive agreements and a licensing deal, with potential income of $20 million and a valuation of $667 million.
• ABVC's flagship product, Vitargus®, is expected to be the first biodegradable hydrogel product used in retinal detachment surgery, with positive results potentially leading to distribution agreements in Asia and Australia.
The story of a company changing the way we treat diseases
ABVC BioPharma, Inc. (NASDAQ: ABVC ), is a clinical-stage biopharmaceutical company with the aim of transforming the oncology/hematology, CNS disorders, and ophthalmology treatment landscape with healthier and innovative therapies with better odds at a positive outcome.
Pioneering the future of neurological and mental health treatments
ABVC Biopharma Inc. has recently gained interest in the investment community. The stock surged by 300% and then retreated on Thursday October 26, 2023 following the company's announcement of a term sheet to license global rights for CNS drugs targeting MDD and ADHD to AiBtl BioPharma for a valuation of $667 million. ABVC is excited about its major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive the multi-product biopharma company forward. ABVC has definitive agreements for the same CNS drugs with Xinnovation for ABV-1504, ABV-1505, and ABV-1601. The licensing deal carries a possible aggregate income of $20 million for ABVC. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. Xinnovation will fund the Phase III trials under the agreement and ABVC gets the global market less the Chinese market.
Xinnovation Therapeutics Co., Ltd. is headquartered in Hangzhou, China, with offices in the United States & Europe. The company has raised over $100 million in funding from leading investors, including Sequoia Capital China, Hillhouse Capital, & OrbiMed.
The ABVC collaboration holds immense potential for both companies.
ABVC, anticipates substantial royalty payments ranging from 5% to 12% based on the projected annual net sales of the licensed drugs in China. The deal could generate approximately $50 million annual revenue for ABVC, with an estimated revenue of $1 billion during the patent life of these products, could be achieved. Figures highlight the Chinese market potential.
ABVC's CNS drugs have been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC commenced the ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. The trials are heading for the interim report, which ABVC expects to complete by the end of 2023.
Vitargus®: A revolutionary hydrogel product for retinal detachment surgery
In ophthalmology, Vitargus® (ABV-1701) is a groundbreaking, advanced-staged and ABVC's flagship product that is expected to be the first biodegradable hydrogel product used in retinal detachment surgery. Vitargus® has completed the feasibility study in Australia and was approved by the Australian Therapeutic Goods Administration (TGA) to initiate the next phase of the trial in two participating sites.
The Science Park Administration in Taiwan approved ABVC’s plan to set up a pilot Good Manufacturing Practice (GMP) facility to produce Vitargus® and to pursue the process development work for manufacturing optimization. This project is proposed by ABVC’s Taiwan affiliate and co-development partner, BioFirst Corporation.
The Phase II trial of Vitargus® is expected to release its results in Q4 2023. If the results are positive, it could lead to distribution agreements in Asia and Australia in early 2024.
According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, driven, in part, by the rising geriatric population worldwide.
Early clinical studies done by the Company indicate Vitargus® has unique properties that could eliminate the need for patients to remain in a face-down position post-surgery, while significantly improving patient comfort and visual acuity during surgical recovery compared to current products available on the market. Vitargus® is believed to be the first biodegradable vitreous substitute to eliminate the need for an additional surgery to remove surgical fluids.Several large pharmaceutical companies are interested in becoming distribution and/or manufacturing partners for Vitargus®. ABVC continues to have active discussions.
FDA approves clinical trial of BLEX 404 for Advanced Non-Small Cell Lung Cancer
The U.S. FDA has approved the Investigational New Drug (IND) application for the proposed clinical investigation of BLEX 404, the primary active ingredient in ABV-1519. This treatment is being co-developed by BioKey, Inc. and by the Rgene Corporation, Taiwan. The study is under review at the Taiwan FDA for approval. With three previous INDs approved by the US FDA for combination therapies of triple-negative breast cancer, myelodysplastic syndromes (MDS), and pancreatic cancer, BLEX 404 is a promising new option in the fight against cancer.
Financial report with forward progress
ABVC BioPharma is making significant strides in its clinical trials and pipeline development thus creating a more financially sound company going forward under an experienced CEO. The company generated $969,783 and $355,797 in revenues for the years ended December 31, 2022 and 2021, respectively, representing an increase of $613,986 or approximately 173%.Despite a net loss of $16,312,374 for the year ended December 31, 2022 compared to $12,035,851 for the year ended December 31, 2021, ABVC BioPharma has received a $3.175 million investment from The Lind Partners to continue clinical trials. This investment will help the company to further develop its pipeline of six drugs and one medical device known as Vitargus®, a biodegradable vitreous substitute that facilitates retina reattachment surgery.
ABVC signed both an agreement with Xinnovation and a term sheet with AiBtl BioPharma to earn licensing fees of up to $20 million from Xinnovation and royalties of 5-12% of net sales from AiBtl BioPharma. The licensed products in the term sheet with AiBtl BioPharma for Major Depressive Disorder (MDD) and Attention-Deficit/Hyperactivity Disorder (ADHD) were valued at $667 million by a third-party evaluation. The new CEO of ABVC has chosen to forgo a salary and instead opted for stock options as a pivotal component of his compensation package. This move demonstrates the CEO’s confidence in the company’s future and its potential for growth.The future financial outlook looks to be improving dramatically for ABVC BioPharma with the flagship product Vitargus® expected to find cash infusion collaboration deals in the near future.
Forging powerful alliances with strategic partners to unlock new opportunities and drive growth
1) BioKey, Inc., a leading producer of dietary supplements in its GMP facility, is set to receive USD $1.0 million from Define Biotech Co. Ltd. amid increasing interest in mushroom-based nutritional supplements. Define Biotech has been granted the right to distribute the nutritional supplement containing Maitake mushrooms in China and Taiwan. Provides contract development and manufacturing services
.2) MerDury BioPharma for New Product Development and Commercialization through BioKey, Inc. collaborative agreement
3) Ramathibidi Hospital in Thailand. Update on Phase II site initiation
4) Srinagarind Hospital in Thailand Vitargus® meeting to discuss Phase II study protocol with the principal investigator and begin training clinical personnel. Agreement Update on Phase II site initiation
5) Sydney Eye Hospital in Australia Receives ethical approval
6) Cedars-Sinai Medical Center conducts some of the studies Phase I study treating depression
7) Rgene Corporation, Taiwan. Co-development partnership
8) AiBtl BioPharma $667 million deal Best Stocks. AiBtl is an American company and intends to go public on NASDAQ in 2024.
9) Xinnovation Licensing agreement Exclusive licensing agreement in China
10) Science Park Administration in Taiwan creating production facility
11) Zhonghui United Technology (Chengdu) Group Co., Ltd Cooperation Agreement to exchange a 20% ownership stake. Do not underestimate the culture for "healthy medicines" in China and all of Asia.
The list of strategic partnerships mentioned above is just the tip of the iceberg. The extensive network of partners is constantly growing and evolving to provide a bright future for investors and customers..
Video investors should not miss
The final word
ABVC Biopharma Inc. is a promising investment with multiple near-term catalysts. The company’s strategic partnerships in neurological and mental health treatments create a promising future. ABVC’s CNS drugs targeting MDD and ADHD have definitive agreements with Xinnovation for ABV-1504, ABV-1505 and ABV-1601, The definitive agreement carries a possible aggregate income of $20 million for ABVC. There is also a licensing deal with AiBtl BioPharma for a valuation of $667 million. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. ABVC’s CNS drug has been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
Investors should keep an eye on ABVC’s major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive its multi-product biopharma company forward. The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC has commenced ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. With all these developments in place, ABVC Biopharma Inc. is poised to make a significant impact in the biopharmaceutical industry. ABVC Biopharma shares could revalue upwards of $35 in 12 months, given the transformational leadership of the current CEO and his team.
Information concerning the derived price projection
The Marketing Sentinel Share price expected to rise
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet Buying while staying silent?
Previously Zacks had a $9.50 valuation before the current news releases.
Zacks reports a $20.20 price target from an analyst $20.20
Given the current direction of ABVC Biopharma under the leadership of its CEO, a $35 share projection in 12 months seems justified.
ABVC BioPharma: A Promising Investment Discover The True Value Of Your Shares: A Comprehensive Guide
11/01/2023 3:10 P.M.
Key Highlights
• ABVC Biopharma has gained interest in the investment community due to strategic partnerships in neurological and mental health treatments.
• The company's CNS drugs targeting MDD and ADHD have definitive agreements and a licensing deal, with potential income of $20 million and a valuation of $667 million.
• ABVC's flagship product, Vitargus®, is expected to be the first biodegradable hydrogel product used in retinal detachment surgery, with positive results potentially leading to distribution agreements in Asia and Australia.
The story of a company changing the way we treat diseases
ABVC BioPharma, Inc. (NASDAQ: ABVC ), is a clinical-stage biopharmaceutical company with the aim of transforming the oncology/hematology, CNS disorders, and ophthalmology treatment landscape with healthier and innovative therapies with better odds at a positive outcome.
Pioneering the future of neurological and mental health treatments
ABVC Biopharma Inc. has recently gained interest in the investment community. The stock surged by 300% and then retreated on Thursday October 26, 2023 following the company's announcement of a term sheet to license global rights for CNS drugs targeting MDD and ADHD to AiBtl BioPharma for a valuation of $667 million. ABVC is excited about its major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive the multi-product biopharma company forward. ABVC has definitive agreements for the same CNS drugs with Xinnovation for ABV-1504, ABV-1505, and ABV-1601. The licensing deal carries a possible aggregate income of $20 million for ABVC. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. Xinnovation will fund the Phase III trials under the agreement and ABVC gets the global market less the Chinese market.
ABVC's CNS drugs have been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC commenced the ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. The trials are heading for the interim report, which ABVC expects to complete by the end of 2023.
Vitargus®: A revolutionary hydrogel product for retinal detachment surgery
In ophthalmology, Vitargus® (ABV-1701) is a groundbreaking, advanced-staged and ABVC's flagship product that is expected to be the first biodegradable hydrogel product used in retinal detachment surgery. Vitargus® has completed the feasibility study in Australia and was approved by the Australian Therapeutic Goods Administration (TGA) to initiate the next phase of the trial in two participating sites.
The Science Park Administration in Taiwan approved ABVC’s plan to set up a pilot Good Manufacturing Practice (GMP) facility to produce Vitargus® and to pursue the process development work for manufacturing optimization. This project is proposed by ABVC’s Taiwan affiliate and co-development partner, BioFirst Corporation.
The Phase II trial of Vitargus® is expected to release its results in Q4 2023. If the results are positive, it could lead to distribution agreements in Asia and Australia in early 2024.
According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, driven, in part, by the rising geriatric population worldwide.
Early clinical studies done by the Company indicate Vitargus® has unique properties that could eliminate the need for patients to remain in a face-down position post-surgery, while significantly improving patient comfort and visual acuity during surgical recovery compared to current products available on the market. Vitargus® is believed to be the first biodegradable vitreous substitute to eliminate the need for an additional surgery to remove surgical fluids.Several large pharmaceutical companies are interested in becoming distribution and/or manufacturing partners for Vitargus®. ABVC continues to have active discussions.
FDA approves clinical trial of BLEX 404 for Advanced Non-Small Cell Lung Cancer
The U.S. FDA has approved the Investigational New Drug (IND) application for the proposed clinical investigation of BLEX 404, the primary active ingredient in ABV-1519. This treatment is being co-developed by BioKey, Inc. and by the Rgene Corporation, Taiwan. The study is under review at the Taiwan FDA for approval. With three previous INDs approved by the US FDA for combination therapies of triple-negative breast cancer, myelodysplastic syndromes (MDS), and pancreatic cancer, BLEX 404 is a promising new option in the fight against cancer.
Financial report with forward progress
ABVC BioPharma is making significant strides in its clinical trials and pipeline development thus creating a more financially sound company going forward under an experienced CEO. The company generated $969,783 and $355,797 in revenues for the years ended December 31, 2022 and 2021, respectively, representing an increase of $613,986 or approximately 173%.Despite a net loss of $16,312,374 for the year ended December 31, 2022 compared to $12,035,851 for the year ended December 31, 2021, ABVC BioPharma has received a $3.175 million investment from The Lind Partners to continue clinical trials. This investment will help the company to further develop its pipeline of six drugs and one medical device known as Vitargus®, a biodegradable vitreous substitute that facilitates retina reattachment surgery.
ABVC signed both an agreement with Xinnovation and a term sheet with AiBtl BioPharma to earn licensing fees of up to $20 million from Xinnovation and royalties of 5-12% of net sales from AiBtl BioPharma. The licensed products in the term sheet with AiBtl BioPharma for Major Depressive Disorder (MDD) and Attention-Deficit/Hyperactivity Disorder (ADHD) were valued at $667 million by a third-party evaluation. The new CEO of ABVC has chosen to forgo a salary and instead opted for stock options as a pivotal component of his compensation package. This move demonstrates the CEO’s confidence in the company’s future and its potential for growth.The future financial outlook looks to be improving dramatically for ABVC BioPharma with the flagship product Vitargus® expected to find cash infusion collaboration deals in the near future.
Forging powerful alliances with strategic partners to unlock new opportunities and drive growth
1) BioKey, Inc., a leading producer of dietary supplements in its GMP facility, is set to receive USD $1.0 million from Define Biotech Co. Ltd. amid increasing interest in mushroom-based nutritional supplements. Define Biotech has been granted the right to distribute the nutritional supplement containing Maitake mushrooms in China and Taiwan. Provides contract development and manufacturing services
.2) MerDury BioPharma for New Product Development and Commercialization through BioKey, Inc. collaborative agreement
3) Ramathibidi Hospital in Thailand. Update on Phase II site initiation
4) Srinagarind Hospital in Thailand Vitargus® meeting to discuss Phase II study protocol with the principal investigator and begin training clinical personnel. Agreement Update on Phase II site initiation
5) Sydney Eye Hospital in Australia Receives ethical approval
6) Cedars-Sinai Medical Center conducts some of the studies Phase I study treating depression
7) Rgene Corporation, Taiwan. Co-development partnership
8) AiBtl BioPharma $667 million deal Best Stocks. AiBtl is an American company and intends to go public on NASDAQ in 2024.
9) Xinnovation Licensing agreement Exclusive licensing agreement in China
10) Science Park Administration in Taiwan creating production facility
11) Zhonghui United Technology (Chengdu) Group Co., Ltd Cooperation Agreement to exchange a 20% ownership stake. Do not underestimate the culture for "healthy medicines" in China and all of Asia.
The list of strategic partnerships mentioned above is just the tip of the iceberg. The extensive network of partners is constantly growing and evolving to provide a bright future for investors and customers..
Video investors should not miss
The final word
ABVC Biopharma Inc. is a promising investment with multiple near-term catalysts. The company’s strategic partnerships in neurological and mental health treatments create a promising future. ABVC’s CNS drugs targeting MDD and ADHD have definitive agreements with Xinnovation for ABV-1504, ABV-1505 and ABV-1601, Thedefinitive agreement carries a possible aggregate income of $20 million for ABVC. There is also a licensing deal with AiBtl BioPharma for a valuation of $667 million. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. ABVC’s CNS has been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
Investors should keep an eye on ABVC’s major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive its multi-product biopharma company forward. The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC has commenced ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. With all these developments in place, ABVC Biopharma Inc. is poised to make a significant impact in the biopharmaceutical industry. ABVC Biopharma shares could revalue upwards of $35 in 12 months, given the transformational leadership of the current CEO and his team.
Information concerning on the derived price projection
The Marketing Sentinel Share price expected to rise
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet Buying while staying silent?
Previously Zacks had a $9.50 valuation before the current news releases.
Zacks reports a $20.20 price target from an analyst $20.20
Given the current direction of ABVC Biopharma under the leadership of its CEO, a $35 share projection in 12 months seems justified.
Disclaimer
I enjoy searching for undervalued micro caps (Invested in ABVC as it fits the profile). Over the years, I have become a biotech fanatic & studying biotech is my passion. All posts are to initiate discussion, definitely not financial advice.
ABVC BioPharma: A Promising Investment With a $35 Per Share Valuation target
11/01/2023 1:00 A.M.
Highlights
• ABVC BioPharma, Inc. (NASDAQ: ABVC), is clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS) disorders, and ophthalmology.
• ABVC Biopharma has gained interest in the investment community due to strategic partnerships in neurological and mental health treatments.
• The company's CNS drugs targeting MDD and ADHD have definitive agreements and a licensing deal, with potential income of $20 million and a valuation of $667 million.
• ABVC's flagship product, Vitargus®, is expected to be the first biodegradable hydrogel product used in retinal detachment surgery, with positive results potentially leading to distribution agreements in Asia and Australia.
About the company
ABVC BioPharma, Inc. (NASDAQ: ABVC), is clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS) disorders, and ophthalmology.
Promising future in neurological and mental health treatments
ABVC Biopharma Inc. has recently gained interest in the investment community. The stock surged by 300% and then retreated on Thursday October 26, 2023 following the company's announcement of a term sheet to license global rights for CNS drugs targeting MDD and ADHD to AiBtl BioPharma for a valuation of $667 million. ABVC is excited about its major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive the multi-product biopharma company forward. ABVC has definitive agreements for the same CNS drugs with Xinnovation for ABV-1504, ABV-1505, and ABV-1601. The licensing deal carries a possible aggregate income of $20 million for ABVC. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. Xinnovation will fund the Phase III trials under the agreement and ABVC gets the global market less the Chinese market.
ABVC's CNS drugs have been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC commenced the ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. The trials are heading for the interim report, which ABVC expects to complete by the end of 2023.
Vitargus®: A groundbreaking hydrogel product for retinal detachment surgery
In ophthalmology, ABVC’s Vitargus® (ABV-1701) is a groundbreaking, advanced-staged flagship product that is expected to be the first biodegradable hydrogel product used in retinal detachment surgery. Vitargus® has completed the feasibility study in Australia and was approved by the Australian Therapeutic Goods Administration (TGA) to initiate the next phase of the trial in two participating sites.
The Science Park Administration in Taiwan approved ABVC’s plan to set up a pilot Good Manufacturing Practice (GMP) facility to produce Vitargus® and to pursue the process development work for manufacturing optimization. This project is proposed by ABVC’s Taiwan affiliate and co-development partner, BioFirst Corporation.
The Phase II trial of Vitargus® is expected to release its results in Q4 2023. If the results are positive, it could lead to distribution agreements in Asia and Australia in early 2024.
According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, driven, in part, by the rising geriatric population worldwide.
Early clinical studies done by the Company indicate Vitargus® has unique properties that could eliminate the need for patients to remain in a face-down position post-surgery, while significantly improving patient comfort and visual acuity during surgical recovery compared to current products available on the market. Vitargus® is believed to be the first biodegradable vitreous substitute to eliminate the need for an additional surgery to remove surgical fluids.Several large pharmaceutical companies are interested in becoming distribution and/or manufacturing partners for Vitargus®. ABVC continues to have active discussions.
FDA approves clinical trial of BLEX 404 for advanced non-small cell lung cancer
The US FDA has approved the Investigational New Drug (IND) application for the proposed clinical investigation of BLEX 404, the primary active ingredient in ABV-1519. This treatment is being co-developed by BioKey, Inc. and by the Rgene Corporation, Taiwan. The study is under review at the Taiwan FDA for approval. With three previous INDs approved by the US FDA for combination therapies of triple-negative breast cancer, myelodysplastic syndromes (MDS), and pancreatic cancer, BLEX 404 is a promising new option in the fight against cancer.
Financials
ABVC BioPharma has been making significant strides in its clinical trials and pipeline development thus creating a more financially sound company going forward under an experienced CEO. The company generated $969,783 and $355,797 in revenues for the years ended December 31, 2022 and 2021, respectively, representing an increase of $613,986 or approximately 173%.Despite a net loss of $16,312,374 for the year ended December 31, 2022 compared to $12,035,851 for the year ended December 31, 2021, ABVC BioPharma has received a $3.175 million investment from The Lind Partners to continue clinical trials. This investment will help the company to further develop its pipeline of six drugs and one medical device known as Vitargus®, a biodegradable vitreous substitute that facilitates retina reattachment surgery.
ABVC has also signed both an agreement with Xinnovation and a term sheet with AiBtl BioPharma to earn licensing fees of up to $20 million from Xinnovation and royalties of 5-12% of net sales from AiBtl BioPharma. The licensed products in the term sheet with AiBtl BioPharma for Major Depressive Disorder (MDD) and Attention-Deficit/Hyperactivity Disorder (ADHD) were valued at $667 million by a third-party evaluation. The new CEO of ABVC has chosen to forgo a salary and instead opted for stock options as a pivotal component of his compensation package. This move demonstrates the CEO’s confidence in the company’s future and its potential for growth.The future financial outlook looks to be improving dramatically for ABVC BioPharma with the flagship product Vitargus® expected to find cash infusion collaboration deals in the near future.
Strategic partnerships
1)BioKey, Inc., a leading producer of dietary supplements in its GMP facility, is set to receive USD $1.0 million from Define Biotech Co. Ltd. amid increasing interest in mushroom-based nutritional supplements. Define Biotech has been granted the right to distribute the nutritional supplement containing Maitake mushrooms in China and Taiwan
.2)ABVC BioPharma has a collaboration agreement with MerDury BioPharma for New Product Development and Commercialization through BioKey, Inc.
3) Ramathibidi Hospital in Thailand. Press release
4) Srinagarind Hospital in Thailand Vitargus® meeting to discuss Phase II study protocol with the principal investigator and begin training clinical personnel. Agreement
5) Sydney Eye Hospital in Australia
6) Cedars-Sinai Medical Center conducts some of the studies
7) Rgene Corporation, Taiwan Rgene. Co-development partnership[color=red][/color]
8) AiBtl BioPharma $667 million deal
9) Xinnovation Licensing agreement
10) Science Park Administration in Taiwan creating production facility
11) Cooperation Agreement to exchange a 20% ownership stake in real estate property of Zhonghui United Technology (Chengdu) Group Co., Ltd. Health and wellness in China. Do not underestimate the culture for "healthy medicines" in China and all of Asia.
The above is not a full list of strategic partnerships as the list is extensive.
Conclusion
ABVC Biopharma Inc. is a promising investment with multiple near-term catalysts. The company’s strategic partnerships in neurological and mental health treatments create a promising future. ABVC’s CNS drugs targeting MDD and ADHD have definitive agreements with Xinnovation for ABV-1504, ABV-1505 and ABV-1601, Thedefinitive agreement carries a possible aggregate income of $20 million for ABVC. There is also a licensing deal with AiBtl BioPharma for a valuation of $667 million. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. ABVC’s CNS has been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
Investors should keep an eye on ABVC’s major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive its multi-product biopharma company forward. The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC has commenced ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. With all these developments in place, ABVC Biopharma Inc. is poised to make a significant impact in the biopharmaceutical industry. ABVC share could revalue upwards of $35 in 12 months given the transformation the CEO and his team are making at ABVC Biopharma.
ABVC BioPharma: A Promising Investment With Multiple Near-Term Catalysts
10/30/2023 8:20 PM EST
Strategic partnerships create a promising future in neurological and mental health treatments
ABVC Biopharma Inc (ABVC) has recently gained interest in the investment community. The stock surged by 300% and then retreated on Thursday October 26, 2023 following the company's announcement of a term sheet to license global rights for CNS drugs targeting MDD and ADHD to AiBtl BioPharma for a valuation of $667 million. ABVC is excited about its major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive the multi-product biopharma company forward. ABVC has definitive agreements for the same CNS drugs with Xinnovation for ABV-1504, ABV-1505, and ABV-1601. The licensing deal carries a possible aggregate income of $20 million for ABVC. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. Xinnovation will fund the Phase III trials under the agreement and ABVC gets the global market less the Chinese market.
ABVC's CNS drugs have been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC commenced the ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. The trials are heading for the interim report, which ABVC expects to complete by the end of 2023.
Vitargus®: A groundbreaking hydrogel product for retinal detachment surgery
In ophthalmology, ABVC’s Vitargus® (ABV-1701) is a groundbreaking, advanced-staged flagship product that is expected to be the first biodegradable hydrogel product used in retinal detachment surgery. Vitargus® has completed the feasibility study in Australia and was approved by the Australian Therapeutic Goods Administration (TGA) to initiate the next phase of the trial in two participating sites. The Science Park Administration in Taiwan approved ABVC’s plan to set up a pilot Good Manufacturing Practice (GMP) facility to produce Vitargus® and to pursue the process development work for manufacturing optimization. This project is proposed by ABVC’s Taiwan affiliate and co-development partner, BioFirst Corporation. The Phase II trial of Vitargus is expected to release its results in Q4 2023. If the results are positive, it could lead to distribution agreements in Asia and Australia in early 2024. According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, driven, in part, by the rising geriatric population worldwide.
FDA approves clinical trial of BLEX 404 for advanced non-small cell lung cancer
The US FDA has approved the Investigational New Drug (IND) application for the proposed clinical investigation of BLEX 404, the primary active ingredient in ABV-1519. This treatment is being co-developed by BioKey, Inc. and by the Rgene Corporation, Taiwan. The study is under review at the Taiwan FDA for approval. With three previous INDs approved by the US FDA for combination therapies of triple-negative breast cancer, myelodysplastic syndromes (MDS), and pancreatic cancer, BLEX 404 is a promising new option in the fight against cancer.
Here's a link for more information: LINK
In conclusion
ABVC Biopharma Inc. is a promising investment with multiple near-term catalysts. The company’s strategic partnerships in neurological and mental health treatments create a promising future. ABVC’s CNS drugs targeting MDD and ADHD have definitive agreements with Xinnovation for ABV-1504, ABV-1505 and ABV-1601, Thedefinitive agreement carries a possible aggregate income of $20 million for ABVC. There is also a licensing deal with AiBtl BioPharma for a valuation of $667 million. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. ABVC’s CNS has been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
Investors should keep an eye on ABVC’s major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive its multi-product biopharma company forward. The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC has commenced ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. With all these developments in place, ABVC Biopharma Inc. is poised to make a significant impact in the biopharmaceutical industry
ABVC BioPharma: A Promising Investment With Multiple Near-Term Catalysts
10/31/2023 8:20 PM EST
Strategic partnerships create a promising future in neurological and mental health treatments
ABVC Biopharma Inc (ABVC) has recently gained interest in the investment community. The stock surged by 300% and then retreated on Thursday October 26, 2023 following the company's announcement of a term sheet to license global rights for CNS drugs targeting MDD and ADHD to AiBtl BioPharma for a valuation of $667 million. ABVC is excited about its major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive its multi-product biopharma company forward. Investors should remember that ABVC has definitive agreements for the same CNS drugs with Xinnovation for ABV-1504, ABV-1505, and ABV-1601. The licensing deal carries a possible aggregate income of $20 million for ABVC. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. Xinnovation will fund the Phase III trials under the agreement and ABVC gets the global market less the Chinese market.
ABVC's CNS has been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, we commenced the ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. The trials are heading for the interim report, which we expect to complete by the end of 2023.
Vitargus®: A groundbreaking hydrogel product for retinal detachment surgery
In ophthalmology, ABVC’s Vitargus® (ABV-1701) is a groundbreaking, advanced-staged flagship product that is expected to be the first biodegradable hydrogel product used in retinal detachment surgery. Vitargus® has completed the feasibility study in Australia and was approved by the Australian Therapeutic Goods Administration (TGA) to initiate the next phase of the trial in two participating sites. The Science Park Administration in Taiwan approved ABVC’s plan to set up a pilot Good Manufacturing Practice (GMP) facility to produce Vitargus® and to pursue the process development work for manufacturing optimization. This project is proposed by ABVC’s Taiwan affiliate and co-development partner, BioFirst Corporation. The Phase II trial of Vitargus is expected to release its results in Q4 2023. If the results are positive, it could lead to distribution agreements in Asia and Australia in early 2024. According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, driven, in part, by the rising geriatric population worldwide.
FDA approves clinical trial of BLEX 404 for advanced non-small cell lung cancer
The US FDA has approved the Investigational New Drug (IND) application for the proposed clinical investigation of BLEX 404, the primary active ingredient in ABV-1519. This treatment is being co-developed by BioKey, Inc. and by the Rgene Corporation, Taiwan. The study is under review at the Taiwan FDA for approval. With three previous INDs approved by the US FDA for combination therapies of triple-negative breast cancer, myelodysplastic syndromes (MDS), and pancreatic cancer, BLEX 404 is a promising new option in the fight against cancer.
Here's a link for more information: Link
In conclusion
ABVC Biopharma Inc. is a promising investment with multiple near-term catalysts. The company’s strategic partnerships in neurological and mental health treatments create a promising future. ABVC’s CNS drugs targeting MDD and ADHD have definitive agreements with Xinnovation for ABV-1504, ABV-1505 and ABV-1601, Thedefinitive agreement carries a possible aggregate income of $20 million for ABVC. There is also a licensing deal with AiBtl BioPharma for a valuation of $667 million. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. ABVC’s CNS has been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
Investors should keep an eye on ABVC’s major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive its multi-product biopharma company forward. The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC has commenced ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. With all these developments in place, ABVC Biopharma Inc. is poised to make a significant impact in the biopharmaceutical industry.
TPST investors should be excited Friday morning because the overall market is expected to be positive, the company is expected to provide an update on its plans for Phase 3 clinical trials of TPST-101, the company is expected to announce a new partnership with a major pharmaceutical company, and the company has a strong financial position with enough cash to fund its operations for the next several years.
Updated Information
Should Investors Be Buying Context Therapeutics (CNTX)?
(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist that's in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This selective binding allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months. The upcoming Society for Immunotherapy of Cancer meeting may alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize CTIM-76 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trials start showing their results be prepared to pony up for shares. There is now an opportunity to invest in CNTX before the bulk of investors come up to speed concerning the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain shareholder excitement as well. Currently they are on the back burner due to prioritization.
Onapristine is one example of an iron in the fire even if it seems to be on hold for now.
As stated by Context Therapeutics they will "explore strategic options for Onapristine-XR." This leaves the possibility of a joint venture concerning Onapristine or sale of Onapristine outright. Due to elevated liver function tests identified in three patients, including in one patient who discontinued treatment, although NONE of the elevated LFTs were considered serious adverse events. The Company determined that significant incremental program costs and delays were likely to be required. Context is a small entity. Cost is the reason the Oath trial is on hold not a failure.
Investors should look up the Onapristine ER trial (Oath) in the Journal of Clinical Oncology.
Why the focus is on CTIM-76 vs Onapristine even though Onapristine has value? The company see's a better path.
It's been found that CTIM-76 is more specific at binding to the desired target CLDN6 than Amgen's candidate AMG 794 Therefore it's possible CTIM-76 gets a collaboration offer or buyout offer that's large. Amgen knows it & here's why. CTIM-76 is found to be approximately 28 times more potent than a competing approach utilizing a bispecific T-cell engager (BITE) format. Don't overlook; Astellas acquired Ganymed & gains access to mAbs targeting CLDN6 (IMAB027) & CLDN18.2 (IMAB362)... CTIM-76 is thought to have more value in treating cancers.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that the forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Like other biotech stocks, share value tends to get heated early when showing potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different; it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to break out and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beatdown has occurred and when the facts on the ground for that investment have not changed. If you have invested that way you have better odds at picking a winner.
Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a baby's development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.
This isn't anything other than my own research and investors must do their own before making a wise decision.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172988579 October 19 run coming?
Should Investors Be Buying Context Therapeutics (CNTX)?
(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist that's in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This selective binding allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months. The upcoming Society for Immunotherapy of Cancer meeting may alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize CTIM-76 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trials start showing their results be prepared to pony up for shares. There is now an opportunity to invest in CNTX before the bulk of investors come up to speed concerning the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain shareholder excitement as well. Currently they are on the back burner due to prioritization.
One such example investors should look up is the Onapristine ER trial (Oath) in the Journal of Clinical Oncology. Oath trial
Below is why the focus is on CTIM-76 vs Onapristine even though it has value
It's been found that CTIM-76 is more specific @ binding to the desired target CLDN6 than Amgen's candidate AMG 794 Therefore it's possible CTIM-76 gets a collaboration offer or buyout offer that's large. Amgen knows it & here's why. CTIM-76 is found to be approximately 28 times more potent than a competing approach utilizing a bispecific T-cell engager (BITE) format. Don't overlook; Astellas acquired Ganymed & gains access to mAbs targeting CLDN6 (IMAB027) & CLDN18.2 (IMAB362)... CTIM-76 is thought to have more value in treating cancers.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that the forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Like other biotech stocks, share value tends to get heated early when showing potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different; it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to break out and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beatdown has occurred and when the facts on the ground for that investment have not changed. If you have invested that way you have better odds at picking a winner.
Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a baby's development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.
This isn't anything other than my own research and investors must do their own before making a wise decision.
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)
Oct. 3, 2023 4:39 PM ET| About: Context Therapeutics Inc. (CNTX), Includes: VKTX
Biotech Rat
Value, Special Situations, Momentum, Long/Short Equity
Summary
CTIM-76, a CLDN6 antagonist developed by Context Therapeutics, shows promise in redirecting T-cell activation towards tumor cells, enhancing safety.
The upcoming Society for Immunotherapy of Cancer meeting may highlight CTIM-76 as a potential blockbuster, leading to a surge in CNTX shares.
Analysts predict a conservative $4 a share or 164.90% increase in CNTX stock within 12 months, with a more realistic target range of $6.25-$15 explained here.
(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist that's in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This selective binding allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months. The upcoming Society for Immunotherapy of Cancer meeting may alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize CTIM-76 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trials start showing their results be prepared to pony up for shares. There is now an opportunity to invest in CNTX before the bulk of investors come up to speed concerning the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain shareholder excitement as well.
One such example is the strategic Partnership with Tyligand Biosciences for Onapristone extended release (ONA-XR) intended for use in hormone-driven breast, ovarian, and endometrial cancer. The partnership seems to be going according to pan. For immediate refresher see the following link. Tyligand Bioscience and Context Therapeutics Sign Strategic Development Agreement for Onapristone ER
Here is a link to the Onapristine ER trial (Oath) in the Journal of Clinical Oncology. Oath trial
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that the forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Like other biotech stocks, share value tends to get heated early when showing potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different; it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to break out and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beatdown has occurred and when the facts on the ground for that investment have not changed. If you have invested that way you have better odds at picking a winner.
Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a baby's development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.
Analyst's Disclosure: I/we have a beneficial long position in the shares of CNTX either through stock ownership, options, or other derivatives.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
Looking at the Context Therapeutics 5 year chart allows for a quick snapshot of the beginning turnaround in the share price .
I think this link reveals how things work. You tell me if you find BNOX flipper driven? Seems it's been pretty hot and for multiple days. Something must be behind that on these otherwise down market days.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172952944
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)
Oct. 3, 2023 4:29 PM ET| About: Context Therapeutics Inc. (CNTX), Includes: VKTX
Biotech Rat
Value, Special Situations, Momentum, Long/Short Equity
Summary
CTIM-76, a CLDN6 antagonist developed by Context Therapeutics, shows promise in redirecting T-cell activation towards tumor cells, enhancing safety.
The upcoming Society for Immunotherapy of Cancer meeting may highlight CTIM-76 as a potential blockbuster, leading to a surge in CNTX shares.
Analysts predict a conservative $4 share price or 164.90% increase in CNTX stock within 12 months, with a more realistic target range of $6.25-$15 explained here.
(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist that's in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months. That's because the upcoming Society for Immunotherapy of Cancer meeting may alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize CTIM-76 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trials start showing their results be prepared to pony up for shares. There is now an opportunity to invest in CNTX before the bulk of investors come up to speed concerning the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain shareholder excitement as well. One example being onapristone extended release (ONA-XR) for use in hormone-driven breast, ovarian, and endometrial cancer. Stay tuned for updates on the robust pipeline as fact checking is near completion. CNTX shares have been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that the forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Like other biotech stocks, share value tends to get heated early when showing potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different; it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to break out and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beatdown has occurred and when the facts on the ground for that investment have not changed. If you have invested that way you have better odds at picking a winner.
Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a baby's development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.
Due your own research and the wise will likely agree.
Disclosure: No recommendation or advice is being given as to whether any investment is suitable for a particular investor.
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)
(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist that's in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months. That's because the upcoming Society for Immunotherapy of Cancer meeting may alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize CTIM-76 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trials start showing their results be prepared to pony up for shares. There is now an opportunity to invest in CNTX before the bulk of investors come up to speed concerning the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain shareholder excitement as well. One example being onapristone extended release (ONA-XR) for use in hormone-driven breast, ovarian, and endometrial cancer. Stay tuned for updates on the robust pipeline as fact checking is near completion. CNTX shares have been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that the forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Like other biotech stocks, share value tends to get heated early when showing potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different; it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to break out and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beatdown has occurred and when the facts on the ground for that investment have not changed. If you have invested that way you have better odds at picking a winner.
Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a baby's development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.
Due your own research and the wise will likely agree.
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)
(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting could alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing their results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain share holder excitement as well. One example being onapristone extended release (ONA-XR) for use in hormone-driven breast, ovarian, and endometrial cancer. Stay tuned for updates on the robust pipeline as fact checking is near completion. CNTX shares have been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to breakout and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beat down has occurred and when the facts on the ground have not changed. If you have done that you have better odds at a winner.
Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a babies development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.
Due your own research and the wise will should agree.
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)
(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting could alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing their results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain share holder excitement as well. Stay tuned for updates on the pipeline as fact checking is near completion. CNTX shares have been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to breakout and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beat down has occurred and when the facts on the ground have not changed. If you have done that you have better odds at a winner.
Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a babies development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.
Due your own research and the wise will should agree.
ARWR was beaten down once and here is another one
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)
(Take a look at CONTEXT Therapeutics) CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CLDN6 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting could alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing their results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the potential market value of a pending CLND6 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain share holder excitement as well. Stay tuned for updates on the pipeline as fact checking is near completion. CNTX shares have been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to breakout and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beat down has occurred and when the facts on the ground have not changed. If you have done that you have better odds at a winner.
Due your own research and the wise will should agree.
VKTX investors look at the similarities
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)
(Take a look at CONTEXT Therapeutics) CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CLDN6 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting could alert investors to a potential blockbuster. CNTX shares could easily climb multiples times higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing their results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the potential market value of a pending CLND6 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain share holder excitement as well. Stay tuned for updates on the pipeline as fact checking is near completion. CNTX stock has been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Look at the 5 year chart and your eye will be open.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to breakout and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. There is a way to invest and that's been proven over and over. Get in early after the beat down is over if the facts on the ground have not changed.
Due your own research and the wise will should agree.
The next BNOX?
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)
(Take a look at CONTEXT Therapeutics) CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CLDN6 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting could alert investors to a potential blockbuster. CNTX shares could easily climb multiples times higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing their results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the potential market value of a pending CLND6 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain share holder excitement as well. Stay tuned for updates on the pipeline as fact checking is near completion. CNTX stock has been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that forecast is far to conservative with a $6-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Look at the 5 year chart and your eye will be open.
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)
(Take a look at CONTEXT Therapeutics) CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CLDN6 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting could alert investors to a potential blockbuster. CNTX shares could easily climb multiples times higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing their results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the potential market value of a pending CLND6 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain share holder excitement as well. Stay tuned for updates on the pipeline as fact checking is near completion. CNTX stock has been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that forecast is far to conservative with a $6-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Look at the 5 year chart and your eye will be open.
Read about this here ad it's soon to act just like PIXY https://investorshub.advfn.com/CNVX-and-other-Bio-techs-cnvx-3716
(Take a look at CNTX) CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CLDN6 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting will alert investors to the potential. CNTX shares could easily climb multiples times higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the market value of a pending CLND6 blockbuster. There are other irons in the fire at Context Therapeutics for share holder excitement as well. Stay tuned for udates on the pipeline as fact checking is near completion. CNTX stock had been beaten down just like the shares of Viking Thereputics(VKTX) Had been before running up to over $25 a share.
Right now the shares of CNTX are held tight and only have a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock stock as a buy. There is a growing consensus that forecast is far to conservative. $6-$15 seems a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this.... Don't believe it? Look over VKTX where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Look at the 5 year chart for CNTX and your eyes will be open.
(Take a look at CNTX) CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CLDN6 to redirect T-cell activation away from where it given the upcoming Society for Immunotherapy of Cancer meeting will alert investors to the potential. CNTX shares could easily climb multiples times higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the market value of a pending CLND6 blockbuster. There are other irons in the fire at Context Therapeutics for share holder excitement as well. Stay tuned for updates on the pipeline as fact checking is near completion. CNTX stock had been beaten down just like the shares of Viking Therapeutics(VKTX) Had been before running up to over $25 a share.
Right now the shares of CNTX are held tight and only have a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock stock as a buy. There is a growing consensus that forecast is far to conservative. $6-$15 seems a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this.... Don't believe it? Look over VKTX where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Look at the 5 year chart and your eye will be open.would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6-$15 a share is reasonable within 12 months
(Take a look at CNTX) CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CLDN6 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting will alert investors to the potential. CNTX shares could easily climb multiples times higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the market value of a pending CLND6 blockbuster. There are other irons in the fire at Context Therapeutics fir share share holder excitement as well. Stay tuned for udates on the pipeline as fact checking is near completion. CNTX stock had been beaten down just like the shares of Viking Thereputics(VKTX) Had been before running up to over $25 a share.
Right now the shares CNTX shares are held tight and only have a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock stock as a buy. There is a growing consensus that forecast is far to conservative. $6-$15 seems a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this.... Don't believe it? Look over VKTX where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Look at the 5 year chart and your eye will be open.
CNTX - CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This will allow CLDN6 to redirect T-cell activation and enhance the safety profile. There is an immense market for and absolute need for high specificity to tumor cells and Context Therapeutics has got a good iron in the fire here. When investors realize claudin 6 is an exceptionally attractive target for big pharma CNTX shares will likely be trading well over $10 a share. At the point clinical trails start showing results be prepared to pony up for shares. Of course there will be opportunity to get in before the bulk of investors learn the market value of a pending success. There are some other irons in the fire here for CNTX share holders. Stay tuned CNTX was taken down just like VKTX shares for a different biotech company and before VKTX running up to the $25 area. More info is forthcoming after fact checking and review of Context Therapeutics pipeline. Right now the shares here are held tight and should really have a small pool being traded. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock stock as a buy. There is a growing consensus that forecast is far to conservative. $10 seems a more realistic target in that time frame. Longer term VKTX had nothing on CNTX. Do some homework and see the opportunity before the masses. Things do get heated early with real potential like this.... Don't believe it? Look over VKTX where this isn't it's first early move. CNTX isn't different.
Look at the way BNOX is trading. Looking at CNTX instead looks like BNOX before the run up. Lower shares than BNOX and ground floor anything under $4 so we are talking really good returns on the upcoming events.
I don't like the way VKTX is trading. Looking at CNTX instead looks like VKTX before the run up. Lower shares than VKTX and ground floor anything under $4 so we are talking really good returns on the upcoming events.
OVERALL FLOW - Bearish for Viking Therapeutics Inc. Up on low volume after a new low in the morning. Did not test the real support today before being manipulated up on low volume. Look for down days ahead. Not worth chasing with an overall bearish indication. The bottom must be tested first.
52 week range $2.59 - $25.7199..... No entry till we test $10.51 and it's not been tested. If VKTX breaks lower it might drop and test the $9's. Todays range at this time $10.67 - $11.31
No way the low does not get tested in the next trading session or next week.